For patients facing rare and often debilitating neurological disorders, specialized treatments like Nulibry, Yorvipath, and Ingrezza offer potential relief and hope. These FDA-approved medications target …

What Are Nulibry, Yorvipath, and Ingrezza? These three medications serve different patient populations with specific conditions that require specialized treatment approaches. Nulibry (fosdenopterin) is the …

This guide explores essential information about Nulibry, Yorvipath, and Ingrezza treatment, three therapies used in managing rare and specific medical conditions. While each medicine targets …

3 days ago · A Phase III trial of Neurocrine Biosciences’ valbenazine in dyskinetic cerebral palsy has missed its primary and key secondary endpoints. The study randomized children and adults with the …

3 days ago · Neurocrine's Ingrezza failed its phase 3 trial for dyskinetic cerebral palsy, missing key goals. Read more here.

Dec 16, 2025 · The company's clinical portfolio includes a rich pipeline of early- to mid-stage muscarinic agonists and VMAT2 inhibitors for the treatment of neuropsychiatric indications, and CRF-based …

View the medication guide of INGREZZA® (valbenazine) capsules for TD. See PI, including Boxed Warning, and Med Guide.

May 29, 2025 · Ingrezza (valbenazine) is used to treat tardive dyskinesia (TD) and chorea associated with Huntington's disease. Ingrezza uses, side effects, doses, and more.

Find treatment guidelines for tardive dyskinesia, including using INGREZZA as a first-line treatment option. See Prescribing Info, including Boxed Warning.

Aug 2, 2024 · Find patient medical information for Ingrezza (valbenazine) on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings